Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
129938-20-1CN(C)[C@@H](CCOc1cccc2ccccc12)c1ccccc1.ClIHWDIQRWYNMKFM-BDQAORGHSA-N129938-20-1DTXSID20926531CHEMBL2106574Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
BeschreibungDapoxetine hydrochloride, belonging to the class of SSRIs, was the first drug originally approved for the on-demand treatment of men with PE by seven European countries in 2008.Premature ejaculation (PE) is the most common male sexual dysfunction. Dapoxetine is a short-acting SSRI. It is differentiated from the existing SSRI treatments for PE by the fact that it can be administered on an as-needed basis. In healthy subjects, dapoxetine is rapidly absorbed after oral administration with a peak plasma concentration (Tmax) occurring between 1.4 and 2h.
VerwendenDapoxetine hydrochloride is a short-acting novel selective serotonin reuptake inhibitor marketed for the treatment of premature ejaculation in men. Premature ejaculation (PE) is the most common male sexual disorder, estimated to affect up to 30% of men.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…